Improvement in body mass index category was associated with improved cardiometabolic measures and patient‐reported outcomes in adults with type 2 diabetes treated with tirzepatide
After tirzepatide treatment, approximately 60% of adults with type 2 diabetes shifted to a lower 'improved' BMI category. This shift was generally associated with numerical improvements in selected cardiometabolic measures and weight-related PROs that may reduce cardiometabolic risk.
Authors
- Hélène Sapin (ORCID: https://orcid.org/0000-0003-2602-8450)
- Russell J. Wiese (ORCID: https://orcid.org/0009-0007-6705-7545)
- Rodolfo Javier Galindo (ORCID: https://orcid.org/0000-0002-9295-3225)
- Clare J. Lee (ORCID: https://orcid.org/0000-0002-0824-0207)
- Kristina S. Boye (ORCID: https://orcid.org/0000-0002-5953-5929)
- Sheryl Allen (ORCID: https://orcid.org/0000-0001-6862-4002)
- Vivian T. Thieu (ORCID: https://orcid.org/0000-0001-9803-4134)
- Wenxiu Dong
- Anne Dib
Institutions
- University of Miami (US)
- Eli Lilly (United States) (US)
- CSL (United States) (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1111/dom.16620
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.18
Funders
- Eli Lilly and Company